Placebo News and Research

RSS

Highland subsidiary begins enrolment in Phase III study of HLD-200 in pediatric ADHD patients

Highland Therapeutics Inc., an emerging pharmaceutical company, today announced that its wholly owned subsidiary has begun enrolment in a Phase III study of HLD-200, the Company's novel formulation of methylphenidate, in pediatric patients with Attention-Deficit Hyperactivity Disorder ("ADHD").

28 Apr 2014

GSK, Theravance announce availability of Anoro Ellipta in the US for COPD treatment

GlaxoSmithKline plc and Theravance, Inc. today announced that Anoro Ellipta (umeclidinium and vilanterol inhalation powder), the first once-daily product approved in the US that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of chronic obstructive pulmonary disease (COPD), is now available to retail pharmacies in the US.

28 Apr 2014

Genervon completes GM604 Phase 2a clinical trial for amyotrophic lateral sclerosis

Genervon Biopharmaceuticals LLC today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis ("ALS") disease modification. A full analysis of the trial's results is expected to be completed in the third quarter of 2014, but preliminary data suggests that Genervon's novel, proprietary, multi-target biological drug candidate, GM604, shows significant promise for treating ALS.

28 Apr 2014

Highlights from April 2014 issue of Mayo Clinic Health Letter

Here are highlights from the April issue of Mayo Clinic Health Letter.

26 Apr 2014

European Commission approves VOKANAMET for treatment of adults with type 2 diabetes mellitus

Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved VOKANAMET® (a fixed-dose therapy combining canagliflozin and immediate release metformin hydrochloride in a single tablet) in the European Union, for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control.

26 Apr 2014

Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Concert Pharmaceuticals, Inc. today announced 48-week results of its Phase 2 clinical trial of CTP-499 in patients with diabetic kidney disease. CTP-499, when used in addition to the standard of care, is being developed to delay the progression of these patients to end-stage renal failure, which requires dialysis or kidney transplantation.

26 Apr 2014

Effects of blueberry powder on blood pressure and arterial stiffness in postmenopausal women

Initial research out of Florida State University investigated whether daily consumption of a freeze-dried blueberry powder supplement resulted in a reduction of blood pressure and arterial stiffness, a measure of cardiovascular disease risk, in postmenopausal women with pre- and stage 1-hypertension.

25 Apr 2014

Aspirin can lower colon cancer risk among people with high levels of specific gene

The humble aspirin may have just added another beneficial effect beyond its ability to ameliorate headaches and reduce the risk of heart attacks: lowering colon cancer risk among people with high levels of a specific type of gene.

25 Apr 2014

Targeting B cells may help reduce disease activity for people with multiple sclerosis

A new study suggests that targeting B cells, which are a type of white blood cell in the immune system, may be associated with reduced disease activity for people with multiple sclerosis (MS).

25 Apr 2014

Study offers evidence supporting use of autologous stem cell-based treatment for stroke

People who have had a stroke, often suffer motor deficits with little potential to restore neurological function.

25 Apr 2014

Methylphenidate may prevent depletion of self-control

Methylphenidate, also known as Ritalin, may prevent the depletion of self-control, according to research published in Psychological Science, a journal of the Association for Psychological Science.

25 Apr 2014

Glaucoma drug may help reverse obesity-related vision loss in women

An inexpensive glaucoma drug, when added to a weight loss plan, can improve vision for women with a disorder called idiopathic intracranial hypertension (IIH), according to a study funded by the National Institutes of Health.

23 Apr 2014

Johns Hopkins scientists find a way to prevent atherosclerosis

Working with mice and rabbits, Johns Hopkins scientists have found a way to block abnormal cholesterol production, transport and breakdown, successfully preventing the development of atherosclerosis, the main cause of heart attacks and strokes and the number-one cause of death among humans. The condition develops when fat builds inside blood vessels over time and renders them stiff, narrowed and hardened, greatly reducing their ability to feed oxygen-rich blood to the heart muscle and the brain.

23 Apr 2014

New studies may offer hope for people with migraine

Two new studies may offer hope for people with migraine. The two studies released today will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014.

23 Apr 2014

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.

23 Apr 2014

FDA approves Cyramza to treat patients with advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has signed an agreement with Smart Assays to develop a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR).

21 Apr 2014

Sarepta Therapeutics plans to submit eteplirsen NDA for treatment of Duchenne muscular dystrophy

Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today announced it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration by the end of 2014 for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).

21 Apr 2014

FDA and EC grant Orphan Drug Designation to Boehringer’s volasertib for acute myeloid leukemia

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML).

21 Apr 2014

Placebo News and Research

Highland subsidiary begins enrolment in Phase III study of HLD-200 in pediatric ADHD patients

GSK, Theravance announce availability of Anoro Ellipta in the US for COPD treatment

Genervon completes GM604 Phase 2a clinical trial for amyotrophic lateral sclerosis

Highlights from April 2014 issue of Mayo Clinic Health Letter

European Commission approves VOKANAMET for treatment of adults with type 2 diabetes mellitus

Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Effects of blueberry powder on blood pressure and arterial stiffness in postmenopausal women

Aspirin can lower colon cancer risk among people with high levels of specific gene

Targeting B cells may help reduce disease activity for people with multiple sclerosis

Study offers evidence supporting use of autologous stem cell-based treatment for stroke

Methylphenidate may prevent depletion of self-control

Glaucoma drug may help reverse obesity-related vision loss in women

Johns Hopkins scientists find a way to prevent atherosclerosis

New studies may offer hope for people with migraine

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

FDA approves Cyramza to treat patients with advanced stomach cancer

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

Sarepta Therapeutics plans to submit eteplirsen NDA for treatment of Duchenne muscular dystrophy

FDA and EC grant Orphan Drug Designation to Boehringer’s volasertib for acute myeloid leukemia

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News